Complete patient enrollment in the Libtayo first-line NSCLC chemotherapy combination Phase 3 study
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 May 2020
- Due
- 31 Dec 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Patient enrollment in the Libtayo Phase 3 first-line NSCLC chemotherapy combination study is expected to be completed in the second half of 2020.”
What we found
Evidence strength A What the grades mean
The February 2021 10-K lists completed patient enrollment in the Phase 3 first-line NSCLC chemotherapy combination study, within its 2020 reporting period. The exact completion date is not stated.
-
A Regeneron Pharmaceuticals 10-K filed 2021-02-08
“Completed patient enrollment in Phase 3 first-line NSCLC chemotherapy combination study” ✓ confirmed on the page
Market reaction: the shares moved -2.2% against the S&P 500 over the three sessions around the disclosure (5 Feb 2021 to 10 Feb 2021). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Patient enrollment completion in Libtayo NSCLC chemotherapy combination Phase 3 study
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Regeneron Pharmaceuticals? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-REGN-006323 · Corrections policy